In the ongoing effort to curb rising drug costs, several states have introduced legislation that would create “drug affordability review boards” tasked with establishing a maximum amount that insurers would pay for drugs when prices rise above a set threshold.In the eyes of the consultant who is helping states develop such measures, this approach to lowering drug costs will both benefit payers and avoid the legal issues that have stymied state efforts in the past.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.